ライフサイエンスコーパス: antibody-drug conjugate

1 xture of protein-rich foods or in generating antibody-drug conjugates).

2 oxin, a chimeric monoclonal antibody, and an antibody drug conjugate.

3 ndent cell killing could be achieved with an antibody-drug conjugate.

4 ingle-chemical entities will be the norm for antibody drug conjugates.

5 l isomer distribution within a population of antibody drug conjugates.

6 onary drug delivery, (vi) implants and (vii) antibody-drug conjugates.

7 tches, inhalers, drug reservoir implants and antibody-drug conjugates.

8 e toxic compounds used in current generation antibody-drug conjugates.

9 eukemia (AML) but has proven challenging for antibody-drug conjugates.

10 critical principles for efficacy, similar to antibody-drug conjugates.

11 account for the potency of disulfide-linked antibody-drug conjugates.

12 therapy, including targeted approaches as in antibody-drug conjugates.

13 cations, including production of therapeutic antibody-drug conjugates.

14 ncers (TNBCs), may be a potential target for antibody-drug conjugates.

15 hesis of new classes of stapled peptides and antibody-drug conjugates.

16 ion of some highly active new agents such as antibody-drug conjugates.

17 The anti-EphA2 antibody-drug conjugate [1C1-maleimidocaproyl-MMAF (mcMM

18 To treat these patients, trastuzumab-based antibody-drug conjugates (ACDs) have been developed and

19 ed understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of r

20 pyrrolobenzodiazepine (PBD)-based anti-CD19 antibody drug conjugate (ADC) being investigated for tre

21 platform to analyze an intact, lysine-linked antibody drug conjugate (ADC) in order to assess post tr

22 perty to selectively target melanoma with an antibody drug conjugate (ADC) specific to PMEL17, the pr

23 However, a novel auristatin E-based antibody drug conjugate (ADC), E-selectin antibody valin

24 phase 2 study assessing the efficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) i

25 s spectrometric (HDX-MS) investigation of an antibody-drug conjugate (ADC) comprised of drug-linkers

26 Here we describe the generation of an antibody-drug conjugate (ADC) consisting of a humanized

27 We generated a novel antibody-drug conjugate (ADC) enfortumab vedotin compris

28 An antibody-drug conjugate (ADC) provides the possibility o

29 We have developed a novel antibody-drug conjugate (ADC) that can selectively deliv

30 Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers

31 Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved recently

32 mitotic monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADC) therapy.

33 By analyzing the antibody-drug conjugate (ADC) using native desalting con

34 A chemically defined anti-CXCR4-auristatin antibody-drug conjugate (ADC) was synthesized that selec

35 Antibody-drug conjugate (ADC) which delivers cytotoxic d

36 ty of using tissue factor as a target for an antibody-drug conjugate (ADC), a panel of human tissue f

37 uctural characterization was performed on an antibody-drug conjugate (ADC), composed of an IgG1 monoc

38 r of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly showing its act

39 preclinical efficacy of BAY 1187982, a novel antibody-drug conjugate (ADC).

40 al antibodies (mAbs) and derivatives such as antibody-drug conjugates (ADC) and bispecific antibodies

41 Antibody-drug conjugates (ADC) are an emerging drug clas

42 Antibody-drug conjugates (ADC) are designed to selective

43 However, many of the compounds used in such antibody-drug conjugates (ADC) are substrates for the mu

44 erization like bsAbs, antibody mixtures, and antibody-drug conjugates (ADC) as well as for biosimilar

45 Antibody-drug conjugates (ADC) comprise targeting antibo

46 Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin

47 Current antibody-drug conjugates (ADC) have made advances in eng

48 ally thought that the anticancer efficacy of antibody-drug conjugates (ADC) relies on their internali

49 Antibody-drug conjugates (ADC) target cytotoxic drugs to

50 Analysis of samples containing intact antibody-drug conjugates (ADC) using mass spectrometry p

51 Antibody-drug conjugates (ADC), potent cytotoxic drugs c

52 ndow that are interesting for application in antibody-drug conjugates (ADC).

53 ic conjugation technology used to synthesize antibody-drug conjugates (ADC).

54 ill target cells, for example in the form of antibody-drug conjugates (ADC).

55 Antibody drug conjugates (ADCs) are macromolecules compo

56 as powerful payloads for the development of antibody drug conjugates (ADCs) intended for personalize

57 ic agents to these nnAAs, yields homogeneous antibody drug conjugates (ADCs) that can be optimized fo

58 cant progress in the clinical application of antibody drug conjugates (ADCs), novel cleavage strategi

59 potencies that qualify them as payloads for antibody drug conjugates (ADCs), while a number of them

60 to antibodies resulting in the generation of antibody drug conjugates (ADCs).

61 Antibody-drug conjugates (ADCs) allow selective targetin

62 e to RPLC-MS for peptide mapping analyses of antibody-drug conjugates (ADCs) and their parent antibod

63 Antibody-drug conjugates (ADCs) are a promising class of

64 Antibody-drug conjugates (ADCs) are among the most promi

65 Antibody-drug conjugates (ADCs) are an important class o

66 Antibody-drug conjugates (ADCs) are designed to facilita

67 Antibody-drug conjugates (ADCs) are promising agents for

68 Antibody-drug conjugates (ADCs) are protein therapeutics

69 Many antibody-drug conjugates (ADCs) are unstable in vivo bec

70 with potential for use in the development of antibody-drug conjugates (ADCs) as well as being clinica

71 part of an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncology indicati

72 Antibody-drug conjugates (ADCs) comprise antibodies cova

73 In this study, we investigated whether antibody-drug conjugates (ADCS) conjugated with pyrrolob

74 strategy for the preparation of homogeneous antibody-drug conjugates (ADCs) containing multiple payl

75 m has been exploited with the development of antibody-drug conjugates (ADCs) for cancer chemotherapy.

76 The field of antibody-drug conjugates (ADCs) has gained significant m

77 Antibody-drug conjugates (ADCs) have a significant impac

78 Bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs) have already demonstrate

79 Therefore, antibody-drug conjugates (ADCs) have been developed to s

80 though recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to ad

81 cytic leukemia (CLL); however, CD37-directed antibody-drug conjugates (ADCs) have not been explored.

82 d in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non-small-cell lung c

83 The recent success of antibody-drug conjugates (ADCs) in the treatment of canc

84 The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-

85 Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a promising anti-canc

86 Antibody-drug conjugates (ADCs) of defined structure hol

87 Antibody-drug conjugates (ADCs) offer increased efficacy

88 Current strategies to produce homogeneous antibody-drug conjugates (ADCs) rely on mutations or ine

89 rogress has been made recently in developing antibody-drug conjugates (ADCs) that can selectively del

90 successfully used to engineer site-specific antibody-drug conjugates (ADCs) that exhibit cytotoxicit

91 Antibody-drug conjugates (ADCs) use antibodies to delive

92 Antibody-drug conjugates (ADCs) were prepared consisting

93 ched to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a number of which are n

94 Preparation of antibody-drug conjugates (ADCs), an emerging novel class

95 Antibody-drug conjugates (ADCs), an increasingly importa

96 geting cytotoxic drugs to cancer cells using antibody-drug conjugates (ADCs), particularly those with

97 tors that are clinically used as payloads in antibody-drug conjugates (ADCs).

98 n synthesized via intermediate 19 for use in antibody-drug conjugates (ADCs).

99 oading on a per-vehicle basis as compared to antibody-drug conjugates (ADCs).

100 of the innate immune system, and constructed antibody-drug conjugates (ADCs).

101 tio (DAR) and catabolite characterization of antibody-drug conjugates (ADCs).

102 h drugs to cysteine thiols for production of antibody-drug conjugates (ADCs).

103 vel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific

104 pproach using an LC-MS/MS experiment from an antibody-drug conjugate and its monoclonal antibody inte

105 tics, such as immunotoxins, immunoliposomes, antibody-drug conjugates and for targeted delivery of ge

106 e natural products as potential payloads for antibody-drug conjugates and other delivery systems for

107 s study are highly desirable as payloads for antibody-drug conjugates and other drug delivery systems

108 ons ranging from probing protein function to antibody-drug conjugates and proteomics.

109 le for the generation of molecularly defined antibody-drug conjugates and radioimmunoconjugates.

110 h the clinical and industrial development of antibody-drug conjugates and small molecule-drug conjuga

111 ging, determining the therapeutic index with antibody drug conjugates, and dosing in radioimmunothera

112 dition of payloads to proteins, synthesis of antibody-drug conjugates, and identification of hyperrea

113 n antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A

114 Our data support the use of an antibody-drug conjugate approach to selectively target a

115 and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FD

116 ber of fields, including therapeutics, where antibody-drug conjugates are an emerging area of biologi

117 However, we found that alpha-amanitin-based antibody-drug conjugates are highly effective therapeuti

118 Antibody-drug conjugates are monoclonal antibodies conju

119 Several promising antibody-drug conjugates are now in late-phase clinical

120 Antibody-drug conjugates are targeted anticancer agents

121 oclonal antibodies (mAbs), including several antibody-drug conjugates, are in advanced clinical devel

122 therapeutic target in CLL and for IgM-based antibody-drug conjugates as a new targeting platform.

123 The advent of antibody-drug conjugates as pharmaceuticals has fuelled

124 fety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, as frontline therapy in 27 HL p

125 A survey of several antibody drug conjugates based on the same IgG framework

126 This was achieved with an antibody drug conjugate between a novel, rationally desi

127 The antibody drug conjugate brentuximab vedotin is a new, hi

128 The antibody drug conjugate brentuximab vedotin is associate

129 by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35).

130 The antibody-drug conjugate brentuximab vedotin delivers the

131 l outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients

132 calize the drug molecules in the therapeutic antibody-drug conjugate brentuximab vedotin, which displ

133 ess was achieved with the development of the antibody-drug-conjugate brentuximab vedotin.

134 he design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastu

135 The CD30-specific antibody-drug conjugate, brentuximab vedotin, is approve

136 monomethyl auristatin E (MMAE) to create the antibody-drug conjugate cAC10-vcMMAE.

137 nd metabolism of the parent antibody and two antibody-drug conjugates, cAC10vc-MMAE and cAC10vc-MMAF,

138 d provide a mechanistic basis for developing antibody-drug conjugates cleavable by intracellular prot

139 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent

140 mab deruxtecan (also known as DS-8201) is an antibody-drug conjugate comprised of a humanised antibod

141 e aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent D

142 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate comprising the cytotoxic agent D

143 biomedicines, including half-life extension, antibody-drug conjugates, conjugate vaccines, bispecific

144 ty in rodent models relative to conventional antibody drug conjugates conjugated through either engin

145 y of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting of a humanized anti-f

146 Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazep

147 Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclo

148 Affinity-attenuated bispecific EGFR x c-MET antibody-drug conjugates demonstrated high in vitro sele

149 plasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33.

150 Current antibody-drug conjugate designs that incorporate a disul

151 Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like prot

152 Antibody drug conjugates enable the targeted delivery of

153 Antibody-drug conjugates enhance the antitumor effects o

154 e studies demonstrated that the antibody and antibody-drug conjugates entering target cells migrated

155 Design of effective antibody-drug conjugates for cancer therapy requires sel

156 ets, enabling the synthesis of site-specific antibody-drug conjugates for selective killing of HER2-p

157 tionale for developing optimally constructed antibody-drug conjugates for treating tumors that expres

158 CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have be

159 The antibody-drug conjugate glembatumumab vedotin consists o

160 The antibody-drug conjugate glembatumumab vedotin links a fu

161 herapeutic antibodies and glycosite-specific antibody-drug conjugates (gsADCs) have generated great i

162 Antibody-drug conjugates have emerged as a powerful stra

163 Antibody-drug conjugates have produced remissions in acu

164 Antibody-drug conjugates hold considerable promise as an

165 r of these therapeutic approaches, including antibody-drug conjugates, immunotoxins, and targeted nuc

166 fety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+)

167 fficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in relapsed/refractory CD30(+)

168 ted by therapeutic anti-ERBB2 antibodies and antibody-drug conjugates, including trastuzumab, trastuz

169 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epiderma

170 Targeted therapy with this CD30-directed antibody-drug conjugate may be an effective treatment fo

171 artic or serine protease inhibitors, blocked antibody-drug conjugate metabolism and the ensuing cytot

172 2 antibodies as model systems, site-specific antibody drug conjugates (NDCs) were produced, via oxime

173 and in tumor xenograft models compared with antibody-drug conjugates of 11D10.

174 BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers an avenue to develop pha

175 The resulting chemically defined antibody-drug conjugates represent the first example in

176 Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a seco

177 rived xenografts, treatment with an anti-5T4 antibody-drug conjugate resulted in complete and sustain

178 The antibody-drug conjugate's mean half-life was 16.5 hours

179 ), radioimmunoconjugates (radionuclide), and antibody drug conjugates (small-molecule drug).

180 a second anti-HER2 agent, and trials of the antibody-drug conjugate T-DM1 (trastuzumab-emtansine) ha

181 osing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antig

182 ety, and preliminary efficacy of SAR3419, an antibody-drug conjugate targeting CD19, in a first-in-ma

183 Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30.

184 demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

185 Antibodies and antibody-drug conjugates targeting the cell surface prot

186 Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selectiv

187 nalytical approach for ADCs, such as THIOMAB antibody-drug conjugates (TDCs), where the linker drugs

188 Trastuzumab emtansine (T-DM1) is an antibody drug conjugate that optimizes delivery of chemo

189 Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor prop

190 Finally, we develop a GPC2-directed antibody-drug conjugate that is potently cytotoxic to GP

191 Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifi

192 Using the principle of antibody-drug conjugates that deliver highly potent cyto

193 protease-cleavable and reductively cleavable antibody-drug conjugates that were effective and stable

194 Antibody-drug conjugate therapy entails targeted killing

195 inical benefit associated with antibodies or antibody-drug conjugates to STEAP1.

196 The antibody-drug conjugate trastuzumab emtansine (T-DM1) co

197 The antibody-drug conjugate trastuzumab emtansine is indicat

198 The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines

199 n inhibitor), antiestrogen therapies, and an antibody-drug conjugate (trastuzumab-DM1).

200 ized and afucosylated antagonistic anti-BCMA antibody-drug conjugate via a noncleavable linker.

201 ety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS.

202 roach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemi

203 commercially relevant yields and can lead to antibody drug conjugates with improved properties relati

204 method was useful for building a homogeneous antibody-drug conjugate with a precise drug-to-antibody

205 SC16LD6.5) is a first-in-class DLL3-targeted antibody-drug conjugate with encouraging initial safety

206 Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients

207 n improve the intratumoral distribution of a antibody-drug conjugate, with implications for improving